PITTSBURGH--(BUSINESS WIRE)--Complexa, Inc., a clinical-stage platform anti-inflammatory and fibrotic disease-focused biopharmaceutical company, announced today that it has completed a $13 million dollar Series B financing. The company will use funds raised to further advance clinical development of two formulations of its lead compound CXA-10. The first is an intravenous formulation which is currently in Phase I clinical trials for a form of acute kidney disease and the second is an oral formulation for a form of chronic kidney disease for which an IND will be filed later this year. JAFCO Life Science Investment, a part of JAFCO Co., Ltd. (“JAFCO”) led the financing round with significant participation from existing investors.
Complexa board members and JAFCO representatives Kenji Harada, Ph.D., and Hironori Hozoji jointly said, “We see very broad potential for Complexa’s technology in fighting inflammatory and fibrotic-based diseases and look forward to seeing the data from Complexa’s advancing CXA-10 clinical programs. There is great interest from large pharmaceutical companies in this type of novel human pathway signaling technology and a large underserved patient population facing the life-threatening inflammatory-based diseases that Complexa is studying.”
Company President and CEO Josh Tarnoff added, “We’re delighted to have JAFCO join the Complexa investor base. The JAFCO team has a long history of being very supportive of its funded companies. They bring highly valued contributions to Complexa.”
Earlier this month, Complexa announced that it began Phase I trials for the treatment of acute kidney injury related to the administration of contrast imaging agents in high-risk patients, CXA-10’s proof of concept indication. This Phase I trial is designed to assess CXA-10’s safety and pharmacokinetics. Through the use of various biomarkers, the study will also demonstrate CXA-10’s mechanism of action and document target organ engagement that will further illuminate its regulation of critical inflammatory pathways.
CXA-10 and related drug candidates in Complexa’s portfolio utilize the body’s own endogenous signaling pathways to promote defense and repair responses, which can be applied to a number of underserved, life-threatening inflammatory-based diseases. Complexa continues its work on oral chronic treatments, and development programs in other inflammatory, neurodegenerative and fibrotic-related therapeutic categories are also under active evaluation.
About Complexa
Complexa, Inc. is a clinical stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The company’s proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) and additional structure/function-related mediators that are designed to treat various diseases. NFAs are cell signaling agents that regulate major inflammatory signaling pathways (e.g., Nrf2, NFkB and HSF). Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa’s technologies act to amplify the existing anti-inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease.
This press release contains “forward-looking statements” concerning the development of Complexa's products, the potential benefits and attributes of such products, and Complexa's expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Complexa undertakes no obligation to update any forward-looking statements for any reason.
For further information please visit www.complexarx.com or contact the company at 412.727.8727.